Spotify Founder's Neko Health Lands $700M for US Invasion

A New Prescription for Healthcare: Proactive, Not Reactive

Daniel Ek is at it again. But this time, the Spotify founder isn't rewiring music. He's coming for your health. His preventative healthcare startup, Neko Health, just landed a staggering $700 million in a Series C funding round to charge into the United States. The round, announced July 15, 2026, was led by Lightspeed Venture Partners and co-led by O.G. Venture Partners, a massive vote of investor confidence in the company's AI-driven medicine. This cash infusion follows a $260 million Series B in January 2025, pushing Neko's total war chest to over $1 billion.

Don't mistake this for just another health-tech app. Co-founded in 2018 with engineer Hjalmar Nilsonne, Neko's mission is audacious: flip the entire healthcare model from reactive treatment to proactive prevention. The core of it all? A 60-minute, non-invasive body scan using a swarm of proprietary sensors—not MRIs—to capture millions of data points from a single person. Europe is already hooked. Over 350,000 people are registered for a scan across its clinics in Sweden and the U.K.

“This funding is a strong vote of confidence in what we set out to do when we opened our first clinic three years ago: a completely new healthcare experience designed to keep people healthy, catch problems early and help prevent disease before it even starts,” said Nilsonne, who's the CEO.

Now, they're coming to America. With fresh capital, Neko is gunning for the world's largest healthcare market, planting its first U.S. flag in New York City later this year.

How Does the Neko Scan Work?

Picture a sleek, futuristic pod straight out of a sci-fi film. That’s the Neko Health experience. For £299 in the U.K. (around $385 USD), you get an hour-long, radiation-free assessment. A firehose of data. Using over 70 different sensors, the scan assesses everything from skin health and moles to cardiovascular function and metabolic markers. And they run a full blood analysis right there on-site.

The whole point is to spot the absolute earliest warnings of conditions like heart disease, stroke, pre-diabetes, and skin cancer. Forget waiting days or weeks for results. Neko delivers its findings almost instantly. Right after the scan, members sit down with a clinician to go through the millions of data points and cook up a personalized action plan.

And they're not stopping there. Neko recently folded in body composition analysis and even data from wearables like the Apple Watch. This gives clinicians a much richer picture of a member’s health, blending what happens in the clinic with real-world activity and sleep. It's this 360-degree view that has investors seeing a colossal opportunity. As Bejul Somaia, Global Partner at Lightspeed Venture Partners, said, “We believe this is one of the most important healthcare companies of our generation, and we're proud to deepen our partnership as they continue to reimagine prevention.”

The American Gamble: Big Market, Big Challenges

Bringing this to the United States is a gutsy move. The US healthcare system is a beast—notoriously complex and wildly expensive, but also an enormous market hungry for disruption. Neko's strategy is to sidestep the insurance labyrinth entirely with a direct-to-consumer, cash-pay model. The company says the U.S. price will be 'commensurate' with its U.K. cost, likely putting it in the $300-$500 range.

Which begs the question: can this reach beyond the wealthy and wellness-obsessed?

The smart money thinks so. The Series C investor list is a who's who of tech and celebrity—Mark Zuckerberg and Priscilla Chan, tennis star Maria Sharapova, and musician will.i.am. Ek also points to the shocking demand in European countries that have free public healthcare, where hundreds of thousands have joined waitlists to pay for a scan. Here's the kicker: Neko reports that an impressive 75% of members book and prepay for their next appointment right after their first one ends.

The company's secret weapon might be control. By designing its own hardware, software, and clinics, Neko owns the user experience from top to bottom, letting it innovate fast. This could be a decisive edge against competitors. This focus on proactive health taps into a seismic shift in medicine toward continuous monitoring and data science, a field where AI's capabilities in healthcare are exploding.

A New Front in the AI Health Revolution

Neko Health's funding isn't happening in a vacuum. It's a huge bet on the power of artificial intelligence to remake diagnostics and preventative medicine. From tech giants to nimble startups like Fireworks AI, companies are in a mad dash to build models that can decipher complex health data. But Neko's approach of collecting millions of longitudinal data points per person could build an unmatched dataset for training future AIs to spot disease with terrifying accuracy.

The early results are promising. For returning members who had previously been flagged with severe conditions, the company reports three out of four were in good health or had their condition under control by their next scan. Early intervention works.

But the path forward is full of hurdles. Neko has to navigate a tangled regulatory environment and prove its screenings lead to better health outcomes—not just create a generation of 'worried well' obsessing over every data point.

New York is the real test. With the first clinic opening later in 2026, all eyes are on Neko. Ek and Nilsonne's vision, born from a simple question—what would healthcare look like if we built it from scratch today?—is about to face its biggest trial. If they succeed, they won't just have a billion-dollar company; they might fundamentally change our relationship with our own bodies.